drugset / Trial / NCT05533892
Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC
Phase 1
Unknown
30 enrolled
Wan-Guang Zhang
BeiGene · collabChen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province · collabChinese Cooperative Group of Liver Cancer · collabGeneis · collabGeneplus-Beijing Co. Ltd. · collabHaplox Biotechnology Co., Ltd. · collabM&R Pharm · collabSimcere Pharmaceutical Co., Ltd · collabYuce Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Nocardia rubra cell wall skeleton plus hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin, lenvatinib and tislelizumab in patients with advanced hepatocellular carcinoma (HCC).
Timeline
- Start
- 2022-09-01
- Primary completion
- 2024-08-31
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Nocardia Rubra Cell Wall Skeleton | Unknown | 400 ug | Subcutaneous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |